Harvard Apparatus postpones $19 million IPO

By
A A A

Harvard Apparatus Regenerative Technology, a Harvard Bioscience carve-out focusing on regenerative medicine, postponed its IPO on Wednesday citing poor market conditions. The Holliston, MA-based company, which was founded in 2009, had expected to raise $18.7 million in its IPO by offering 1.7 million shares at $10 to $12. Summer Street Research Partners and Maxim Group LLC were set to be the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: HART

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com